What's in Arcutis Biotherapeutics, Inc.'s pipeline?

Arcutis Biotherapeutics, Inc. has 15 drugs in our index: 0 marketed, 0 filed, 8 in Phase 3, 2 in Phase 2, 5 in Phase 1.

Which companies overlap with Arcutis Biotherapeutics, Inc.'s portfolio?

Top competitors by shared drug class: Pfizer, LEO Pharma, AbbVie, Galderma R&D, GlaxoSmithKline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/arcutis-biotherapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Arcutis Biotherapeutics, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Arcutis Biotherapeutics, Inc. pipeline: 0 marketed, 0 filed, 8 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 8 Phase 3 2 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%	ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%	phase 3	Aryl hydrocarbon receptor (AhR) agonist	AhR (Aryl hydrocarbon receptor)	Dermatology
ARQ-151 vehicle cream	ARQ-151 vehicle cream	phase 3	Phosphodiesterase 4 (PDE4) inhibitor	PDE4	Dermatology
Roflumilast Foam 0.3%	Roflumilast Foam 0.3%	phase 3	Phosphodiesterase-4 (PDE-4) inhibitor	PDE-4	Dermatology
ARQ-151 cream 0.3%	ARQ-151 cream 0.3%	phase 3	Phosphodiesterase 4 (PDE4) inhibitor	PDE4	Dermatology
Roflumilast Cream 0.05%	Roflumilast Cream 0.05%	phase 3	Phosphodiesterase-4 (PDE-4) inhibitor	PDE-4	Dermatology
Roflumilast Foam	Roflumilast Foam	phase 3	Phosphodiesterase-4 (PDE-4) inhibitor	PDE-4	Dermatology
Roflumilast Cream 0.15%	Roflumilast Cream 0.15%	phase 3	Phosphodiesterase 4 inhibitor	Phosphodiesterase 4	Immunology
Topical roflumilast	Topical roflumilast	phase 3	phosphodiesterase 4 inhibitor	phosphodiesterase 4	Dermatology

Therapeutic area mix

Dermatology · 10
Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 3 shared drug classes
LEO Pharma · 2 shared drug classes
AbbVie · 2 shared drug classes
Galderma R&D · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Almirall, S.A. · 2 shared drug classes
Amgen · 2 shared drug classes
Alfasigma S.p.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Arcutis Biotherapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Arcutis Biotherapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/arcutis-biotherapeutics-inc. Accessed 2026-05-16.